About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a Healthcare company based in Boston (United States) founded in 1996, and was acquired by Paratek Pharma in July 2014. Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Transcept Pharmaceuticals has raised $40 million across 2 funding rounds from investors including Hercules Capital, Paratek Pharma and New Leaf Venture Partners. Transcept Pharmaceuticals has completed 1 acquisition, including Novacea. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Transcept Pharmaceuticals, Inc. Its competitors include Insmed, Affinivax and Lodo Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Paratek is focused on the discovery, development, and commercialization of medicines that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Lead product candidate, omadacycline (phase 3), is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections. It is also developing sacrecycline (phase 3) for acne in partnership with Allergan. Other pipeline compounds include 2 molecules in phase 3 for acquired bacterial pneumonia infections and skin structure infections.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Website transcept.com
- Social LinkedIn
- Acquired by Paratek Pharma (Jul 2014)
- Legal Name Transcept Pharmaceuticals, Inc
- Total Equity Funding$40M (USD)
in 2 rounds
- Latest Funding Round$40M (USD), Series D
Mar 2007
- InvestorsHercules Capital
& 8 more
- Investments & Acquisitions
- Acquired byParatek Pharma
(Jul 2014)
Funding Insights of Transcept Pharmaceuticals
Transcept Pharmaceuticals has successfully raised a total of $40M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $40 million completed in March 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 2
- Last Round Series D β $40M
- Investors Count 8
All 2 funding rounds of Transcept Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2007 | $40M | Series D | β | β | |
| Jun 2001 | Series A | β | β |
9 investors in total: 9 institutional.
Investors in Transcept Pharmaceuticals
Transcept Pharmaceuticals has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital, Paratek Pharma and New Leaf Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Growth capital investments are made in healthcare and fintech companies. | mepvc.com | San Francisco, United States | ||
Early-stage US tech startups are invested in by Peninsula Ventures. | peninsulaventures.com | San Mateo, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Therapeutics for antimicrobial resistant infections are developed. | 1996 | paratekpharma.com | Boston, United States |
Investor details for Transcept Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Transcept Pharmaceuticals
Transcept Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Novacea.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Serotonin inhibitor drugs for cancer are developed by Novacea. | novacea.com | Richmond, United States | 2001 | Sep 2008 | β’β’β’β’ |
Complete acquisition details for Transcept Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Transcept Pharmaceuticals
6 dated milestones of Transcept Pharmaceuticals across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Transcept Pharmaceuticals is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Series D, of $40.0M.
- Acquisition Acquires Novacea.
- Exit Acquired by Paratek Pharma.
Competitors of Transcept Pharmaceuticals
Transcept Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Lodo Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI |
Detailed competitors of Transcept Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Transcept Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Transcept Pharmaceuticals
Complete news archive for Transcept Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transcept Pharmaceuticals
Transcept Pharmaceuticals was founded in 1996 and raised its 1st funding round 5 years after it was founded.
Transcept Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Transcept Pharmaceuticals is a funded company, having raised a total of $40M across 2 funding rounds to date.
Paratek is focused on the discovery, development, and commercialization of medicines that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Lead product candidate, omadacycline (phase 3), is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections. It is also developing sacrecycline (phase 3) for acne in partnership with Allergan. Other pipeline compounds include 2 molecules in phase 3 for acquired bacterial pneumonia infections and skin structure infections.
Transcept Pharmaceuticals's top competitors include Insmed, Affinivax and Lodo Therapeutics.
Transcept Pharmaceuticals has made 1 acquisition, including Novacea.
Transcept Pharmaceuticals has 9 investors. Key investors include Hercules Capital, Paratek Pharma, New Leaf Venture Partners, NEA, and InterWest.
Transcept Pharmaceuticals operates through Transcept Pharmaceuticals, Inc.
Yes. Transcept Pharmaceuticals was acquired by Paratek Pharma in July 2014.

